Aims: Intramuscular epinephrine (adrenaline) is classified as first-line treatment of choice for anaphylaxis in international and national guidelines. Patients at risk are recommended to be prescribed 2 epinephrine auto-injectors (EAIs) which they should carry with them at all times. A prospective, web-based survey was conducted to obtain insight into adherence to treatment recommendations according guidelines, and postanaphylaxis behavior in patients at risk for anaphylaxis and their caregivers.
